DOCSLIB.ORG

Program and Papers on New Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Program and Papers on New Research PROGRAM AND PAPERS ON NEW RESEARCH IN SUMMARY FORM THE ONE HUNDRED AND FORTY-FIFTH ANNUAL MEETING OF THE AMERICAN PSYCHIATRIC ASSOCIATION WASHINGTON, DC May 2-7, 1992 Papers presented at New Research Sessions are not automatically the property of the American Journal of Psychiatry. Authors are free to submit them to the American Journal of Psychiatry, the Journal of Hospital & Community Psychiatry, or another publication of their choice. SUBCOMMITTEE ON NEW RESEARCH OF THE SCIENTIFIC PROGRAM COMMITTEE Allan Tasman, M.D., Chairperson Craig N. Karson, M.D. Scientific Program Committee Little Rock, AR Louisville, KY Susan J. Fiester, M.D., Chairperson Jeffrey A. Lieberman, M.D. New Research Subcommittee Glen Oaks, NY Nashua, NH Raymond Cohen, M.D. Philip R. Muskin, M.D. Cincinnati,OH New York, NY Outside Reviewers for the New Research Program Nancy C. Andreasen, M.D. Robert M. Post, M.D. Wade H. Berrettini, M.D. William Z. Potter, M.D. Richard l. Borison, M.D. Frederic M. Quitkin, M.D. Gabrielle A. Carlson, M.D. Murray A. Raskind, M.D. Glen C. Davis, M.D. Stephen G. Rayport, M.D. Abby J. Fyer, M.D. Peter P. Roy-Byrne, M.D. Elliott S. Gershon, M.D. Charles A. Shamoian, M.D. Ira D. Glick, M.D. Larry J. Siever, M.D. Judith H. Gold, M.D. Andrew E. Skodol, M.D. Jack M. Gorman, M.D. Robert l. Spitzer, M.D. Katherine A. Halmi, M.D. Michael J. Stanley, M.D. Dilip V. Jeste, M.D. Marvin Stein, M.D. Donald F. Klein, M.D. James J. Strain, M.D. Joel E. Kleinman, M.D. Trey Sunderland, M.D. Donald S. Kornfeld, M.D. James W. Thompson, M.D. Michael R. Liebowitz, M.D. Thomas W. Uhde, M.D. Markku I. Linnoila, M.D. Fred R. Volkmar, M.D. Robert W. McCarley, M. D. B. Timothy Walsh, M.D. John M. Morihisa, M.D. Daniel R. Weinberger, M.D. Charles B. Nemeroff, M.D. George E. Woody, M.D. Charles P. O'Brien, M.D. Stuart C. Yudofsky, M.D. David Pickar, M. D. NEW~ RESEARCH Monday, May 4, 1992, 9:00 a.m.-10:30 a.m. New Research 1-Poster Session-Hall 0, Level 1, Convention Center YOUNG INVESTIGATORS' POSTER SESSION Moderator: Harold Alan Pincus, M.D. NR1 Information Processing Effect on Saccadic Reaction Time in Schizophrenia Douglas M. Berger, M.D., Shinnichi Nezu, M.D., Tomie Iga, B.S., Takashi Hosaka, M.D., Seiro Nakamura, M.D. NR2 Schizophrenia After Prenatal Exposure to Famine Ezra S. Susser, M.D., Lin P. Shang, Ph.D. NR3 Depression in First-Episode Schizophrenia Amy R. Koreen, M.D., Jeffrey A. Lieberman, M.D., Samuel C. Siris, M.D., Miranda Chakos, M.D., Jose Alvir, Dr. P.H., David I. Mayerhoff, M.D. NR4 Plasma HVA in First-Episode Schizophrenia Amy R. Koreen, M.D., Jeffrey A. Lieberman, M.D., Jose Alvir, Dr. P.H., David I. Mayerhoff, M.D., Antony Loebel, M.D., Miranda Chakos, M.D., Thomas Cooper, M.A. NR5 Schizophrenia: Correlated Onset of Comorbid Symptoms James M. Russell, M.D., Lee N. Robins, Ph.D., John P. Rice, Ph.D. NR6 Study of Relapse in Medication Compliant Schizophrenics Sandra Steingard, M.D., Krishna R. Khambampati, M.D., Maureen Allen, M.P.H. NR7 Delayed Effects of CRH and ACTH on Dopamine in Man Joel A. Posener, M.D., Joseph J. SChildkraut, M.D., Gordon H. Williams, M.D., Melinda S. Salomon, Ph.D., Nancy L. McHale, B.S., Alan F. Schatzberg, M.D. NRB Comorbidity in First-Episode Psychosis Stephen M. Strakowski, M.D., Mauricio Tohen, M.D., Andrew L. Stoll, M.D., Gianni L. Faedda, M.D., Pierre V. Mayer, M.D., Meridith L. Kolbrener, B.A., Daniel C. Goodwin NR9 Neuroimaging in Relatives of Schizophrenics Jeremy M. Silverman, Ph.D., Richard S.E. Keefe, Ph.D., Miklos F. Losonczy, M.D., Richard C. Mohs, Ph.D., Larry J. Siever, M.D., Kenneth L. Davis, M.D. NR10 In Vivo Proton Magnetic Resonance Spectroscopy in Never Treated Schizophrenics Jeff A. Stanley, M.Sc., Peter C. Williamson, M.D., Dick J. Drost, Ph.D., Tom Carr, M.D., Jane Rylett, Ph.D., Harold Merskey, D.M. NR11 Executive Impairment in Schizophrenia and Old Age Don R. Royall, M.D., Roderick Mahurin, Ph.D., Janet True, M.D., Brent Anderson, M.S., A. Miller, M.D. NR12 Adjuvant to Neuroleptics in Chronic Schizophrenia Pierre-Michel N Llorca, Marc A. Wolf, Thierry C. Bougerol, Christophe Lancon, Jean Claude Scotto NR13 Subgroups of Schizophrenics Responding to Adjuvant Treatment Pierre-Michel N Llorca, Thierry C. Bougerol, Marc A. Wolf, Christophe Lancon, Jean Claude Scotto NR14 Interleukin-1 and Interleukin-2 in the CSF of Schizophrenic Subjects Rifaat S. EI-Mallakh, M.D., Richard Jed Wyatt, M.D. 1 NR15 Medical Education: Computer Assisted Patient Education T. Bradley Tanner, M.D., Stuart Gitlow, M.D. NR16 The Longitudinal Importance of Expressed Emotion Suzanne King, Ph.D. NR17 Remoxipride in the Treatment of Schizophrenia Sanford Herman, M.D" Mark Weilgus, Ph.D., Carol Hermann, M.D., Andrea Berman, Ph.D., Kathleen O'Connor, B.A., John Herrera, Ph.D. NR18 Biological Analysis in Schizophrenic Patients Felicidad Rodriguez, M.D., Jesus Ezcurra, M.D. NR19 Cingulate Gyrus in Schizophrenia Versus Controls J. Thomas Noga, M.D., Elizabeth Aylward, Ph.D., Godfrey D. Pearlson, M.D. NR20 Prolactin Decrease and Response to Haloperidol Howard H.J. Chang, M.D., Alan I. Green, M.D., Roger A. Boshes, M.D., Mohammed Y. Alam, M.D., Joseph J. Schildkraut, M.D. NR21 Clozapine Versus Haldol in Schizophrenia: A PET Study Daniel Z. Press, B.A., Karen Faith Berman, M.D., Llewellyn B. Bigelow, M.D., Thomas Noga, M.D., Jill L. Ostrem, B.A., James Gold, Ph.D., Daniel R. Weinberger, M.D. NR22 Planum Temporal in Schizophrenia: A Magnetic Resonance Study Alessandro Rossi, Antonio Serio, M.D., Paolo Stratta, M.D., Concetta Petruzzi, M.D., Giovanni Schiazza, M.D., Massimo Casacchia, M.D. NR23 Integrating Psychosocial Treatment on an Inpatient Schizophrenia Research Unit: A Model for Multidisciplinary Psychoeducation Ellen Lukens, C.S.W., Kay D. Gimmestad, B.S., Helle Thorning, M.S.W., Ann Feinstein, OTR, Helen Deustch, R.N., Barbara Angell, R.N. NR24 Information Processing Deficits in Psychoses Esther F. Rabinowicz, Ph.D., Lewis A. Opler, M.D., David R. Owen, Ph.D., Raymond A. Knight, Ph.D. NR25 Factor Structure of the Neurological Evaluation Scale in Schizophrenia Laurence P. Karper, M.D., Morris Bell, Ph.D., Paul Lysaker, Ph.D., Joseph Goulet, M.S., John P. Seibyl, M.D., Joseph P. Erdos, M.D., Louise Brenner, M.S.N., John H. Krystal, M.D. NR26 Clozapine and Slow Wave Sleep in Schizophrenia Jon F. Chaffee, M.D., Steven G. Potkin, M.D., Joseph Wu, M.D. NR27 Heterogeneity in Serotonin Response in Chronic Schizophrenia Ad itayanjee , M.D., Jean-Pierre Lindenmayer, M.D., Sandra Grochowski, B.A., N. Bark, M.D., N. Moynihan, B.S.N. NR28 Comparison of Paranoid and Schizoid Personalities Mark Fulton, M.D., George Winokur, M.D. NR29 Abnormal Laterality in Parents and Schizophrenics Ellen M. Smith, M.D., Nancy Docherty, Ph.D., Bruce Wexler, M.D. NR30 PET in Frontal Head Injury and Striatal Metabolism Stephen Lottenberg, M.D., Nicole Theuvenet; Michelle Solano, Ronald M. Ruff, Ph.D., Jill Stanley, Monte S. Buchsbaum, M.D. NR31 Dopamine Effects on Hippocampal N-Methyl-D-Aspartate Responses Stephen J. Schertzer, M.D., Liang Zhang, M.D., Peter L. Carlen, M.D. 2 NR32 Hypoxia Improves Human Cognitive Function Thomas E. Schlaepfer, M.D. NR33 Effects of Adinazolam and N-Desmethyl Adinazolam Karon Dawkins, M.D., Robert P. Irwin, M.D., Richard L. Hauger, M.D., Joseph C. Fleishaker, Ph.D., William Z. Potter, M.D. NR34 Ictal EEG Effects of ECT Stimulus Intensity Andrew D. Krystal, M.D., Richard D. Weiner, M.D., Pamela K. Smith, Rebekka Arias, C. Edward Coffey, M.D. NR35 Schizotypy and Right Hemisphere Function in Mescaline-Induced Psychosis Godehard Oepen, M.D., Matthias Funfgeld, Anne Harrington, Ph.D., Gordon Claridge, Ph.D., Hanno Botsch, M.D. NR36 Fine Motor Performance in Schizophrenia Jay M. Griffith, M.D., Lawrence E. Adler, M.D., Robert Freedman, M.D. NR37 Pharmacodynamic Response to Intravenous Idazoxan Robert C. Risinger, M.D., Mark E. Schmidt, M.D., Ivan N. Mefford, Ph.D., William Z. Potter, M.D. NR38 Relationship of Low Baseline TSH to TRH Response Deborah Deas-Nesmith, M.D., William Carson, M.D., Shannon Little, M.D., Raymond Anton, M.D. NR39 Ratings of Aggression in Autistic Children Nilda M. Gonzalez, M.D., Monique Ernst, M.D., Jana Signe, BA, Magda Campbell, M.D., Joan Welkowitz, Ph.D. NR40 Malignant Catatonia: Sequelae and Treatment Kemuel L. Philbrick, M.D., Teresa A. Rummans, M.D. NR41 The Immunological Profile of Patient's with Alzheimer's Disease Jerzy W. Leszek, M.D., August Wasik, M.D., Barbara Siesak, Ph.D. NR42 MR Interuncal Distance in Alzheimer's and Parkinson's Disease Bridget Early, MA, Rodrigo Escalona, M.D., William M. McDonald, M.D., P. Murali Doraiswamy, M.D., David Axelson, B.A., K. Ranga Rama Krishnan, M.D. NR43 Noradrenergic System Changes Induced by Electroconvulsive Shock Stephen K. Brannan, M.D., David J. Jones, Ph.D., Alexander Miller, M.D. NR44 The Hawaii Experience with Water Intoxication Linda S. Godleski, M.D., Kenneth Luke, M.D., Barry Carlton, M.D. NR45 Differential Induction of Early Genes by Neuroleptics Patrick Rogue, M.D., Anant N. Malviya, Ph.D., Guy Vincendon, M.D. NR46 Transcription Block and Reduced Nuclear Protein Kinase C Activation During Aging Patrick Rogue, M.D., Guy Vincendon, M.D., Anant N.
Load more

Recommended publications
  • Pindolol of the Activation of Postsynaptic 5-HT1A Receptors
    Potentiation by (-)Pindolol of the Activation of Postsynaptic 5-HT1A Receptors Induced by Venlafaxine Jean-Claude Béïque, Ph.D., Pierre Blier, M.D., Ph.D., Claude de Montigny, M.D., Ph.D., and Guy Debonnel, M.D. The increase of extracellular 5-HT in brain terminal regions antagonist WAY 100635 (100 ␮g/kg, i.v.). A short-term produced by the acute administration of 5-HT reuptake treatment with VLX (20 mg/kg/day ϫ 2 days) resulted in a inhibitors (SSRI’s) is hampered by the activation of ca. 90% suppression of the firing activity of 5-HT neurons somatodendritic 5-HT1A autoreceptors in the raphe nuclei. in the dorsal raphe nucleus. This was prevented by the The present in vivo electrophysiological studies were coadministration of (-)pindolol (15 mg/kg/day ϫ 2 days). undertaken, in the rat, to assess the effects of the Taken together, these results indicate that (-)pindolol coadministration of venlafaxine, a dual 5-HT/NE reuptake potentiated the activation of postsynaptic 5-HT1A receptors inhibitor, and (-)pindolol on pre- and postsynaptic 5-HT1A resulting from 5-HT reuptake inhibition probably by receptor function. The acute administration of venlafaxine blocking the somatodendritic 5-HT1A autoreceptor, but not and of the SSRI paroxetine (5 mg/kg, i.v.) induced a its postsynaptic congener. These results support and extend suppression of the firing activity of dorsal hippocampus CA3 previous findings providing a biological substratum for the pyramidal neurons. This effect of venlafaxine was markedly efficacy of pindolol as an accelerating strategy in major potentiated by a pretreatment with (-)pindolol (15 mg/kg, depression.
    [Show full text]
  • HIV and Substance Use October 2016
    HIV and Substance Use October 2016 Fast Facts • Alcohol and other drugs can affect a person’s judgment and increase risk of getting or transmitting HIV. • In people living with HIV, substance use can worsen the overall consequences of HIV. • Social and structural factors make it difficult to prevent HIV among people who use substances. Substance use disorders, which are problematic patterns of using alcohol or another substance, such as crack cocaine, methamphetamine (“meth”), amyl nitrite (“poppers”), prescription opioids, and heroin, are closely associated with HIV and other sexually transmitted diseases. Injection drug use (IDU) can be a direct route of HIV transmission if people share needles, syringes, or other injection materials that are contaminated with HIV. However, drinking alcohol and ingesting, smoking, or inhaling drugs are also associated with increased risk for HIV. These substances alter judgment, which can lead to risky sexual behaviors (e.g., having sex without a condom, having multiple partners) that can make people more likely to get and transmit HIV. In people living with HIV, substance use can hasten disease progression, affect adherence to antiretroviral therapy (HIV medicine), and worsen the overall consequences of HIV. Commonly Used Substances and HIV Risk • Alcohol. Excessive alcohol consumption, notably binge drinking, can be an important risk factor for HIV because it is linked to risky sexual behaviors and, among people living with HIV, can hurt treatment outcomes. • Opioids. Opioids, a class of drugs that reduce pain, include both prescription drugs and heroin. They are associated with HIV risk behaviors such as needle sharing when injected and risky sex, and have been linked to a recent HIV outbreak.
    [Show full text]
  • Advisory Council on the Misuse of Drugs
    ACMD Advisory Council on the Misuse of Drugs Chair: Dr Owen Bowden-Jones Secretary: Zahi Sulaiman 1st Floor (NE), Peel Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 1121 [email protected] Sarah Newton MP Minister for Vulnerability, Safeguarding and Countering Extremism Home Office 2 Marsham Street London SW1P 4DF 10 March 2017 Dear Minister, RE: Further advice on methylphenidate-related NPS In February 2016, my predecessor Professor Les Iversen wrote to the then minister for Preventing Abuse, Exploitation and Crime, requesting that the Temporary Class Drug Order (TCDO) on seven methylphenidate-related Novel Psychoactive Substances be re-laid for a further 12 months. This TCDO was re-laid until June 2017, to allow the Advisory Council on the Misuse of Drugs (ACMD) more time to collect the evidence required to provide further advice for full control under the Misuse of Drugs Act 1971. The ACMD believes that the TCDO has been effective in reducing the prevalence of these substances and that the TCDO level of control was proportionate in the interim. I am now pleased to present to you the ACMD’s further advice on this matter in the enclosed report. The ACMD’s recommendation for full control applies to the seven substances currently controlled under the TCDO and extends to an additional five closely-related substances. These five similar substances have subsequently appeared on markets following the TCDO and are included in this advice due to their potential for similar harms. Recommendation The ACMD recommends that the
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Needle Sharing Among Intravenous Drug Abusers: National and International Perspectives
    Needle Sharing Among Intravenous Drug Abusers: National and International Perspectives U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Needle Sharing Among Intravenous Drug Abusers: National and International Perspectives Editors: Robert J. Battjes, D.S.W. Roy W. Pickens, Ph.D. Division of Clinical Research National Institute on Drug Abuse NIDA Research Monograph 80 1988 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. MARY L. JACOBSON Temple University School of Medrcrne National Federation of Parents for Philadelphia. Pennsylvania Drug-Free Youth Omaha, Nebraska SYDNEY ARCHER, Ph.D. Rensselaer Polytechnic Institute Troy, New York REESE T. JONES, M.D. Langley Porter Neuropsychiatric lnstitute RICHARD E. BELLEVILLE. Ph.D. San Francisco, California NB Associates, Health Sciences RockviIle, Maryland DENISE KANDEL, Ph.D. KARST J. BESTEMAN College of Physicians and Surgeons of Alcohol and Drug Problems Association Columbia University of North America New York, New York Washington, D.
    [Show full text]
  • Epidemics of HIV, HCV and Syphilis Infection Among Synthetic Drugs
    www.nature.com/scientificreports OPEN Epidemics of HIV, HCV and syphilis infection among synthetic drugs only users, heroin-only users and Received: 7 November 2017 Accepted: 28 March 2018 poly-drug users in Southwest China Published: xx xx xxxx Shu Su1, Limin Mao 2, Jinxian Zhao3, Liang Chen3, Jun Jing4, Feng Cheng4 & Lei Zhang 1,4,5 The number of poly-drug users who mix use heroin and synthetic drugs (SD) is increasing worldwide. The objective of this study is to measure the risk factors for being infected with hepatitis C (HCV), human immunodefciency virus (HIV) and syphilis among SD-only users, heroin-only users and poly- drug users. A cross-sectional study was conducted in 2015 from a national HIV surveillance site in Southwest China, 447 poly-drug, 526 SD-only and 318 heroin-only users were recruited. Poly-drug users have higher drug-use frequency, higher rates of drug-sharing and unsafe sexual acts than other users (p < 0.05). About a third (36.7%) of poly-drug users experienced sexual arousal due to drug efects, which is higher than the rate among other drug users. Poly-drug users had the highest prevalence of HIV (10.5%) and syphilis (3.6%), but heroin-only users had the highest prevalence of HCV (66.0%) (all p < 0.05) among three groups. Logistic regression shows among poly-drug users, having sex following drug consumption and using drugs ≥1/day were the major risk factors for both HIV (Adjusted odds ratio (AOR) = 2.4, 95% CI [1.8–3.4]; 2.3, [1.6–3.1]) and syphilis infection (AOR = 4.1, [2.1–6.9]; 3.9, [1.8–5.4]).
    [Show full text]
  • Modulation of Dialysate Levels of Dopamine, Noradrenaline
    Modulation of Dialysate Levels of Dopamine, Noradrenaline, and Serotonin (5-HT) in the Frontal Cortex of Freely-Moving Rats by (-)-Pindolol Alone and in Association with 5-HT Reuptake Inhibitors: Comparative Roles b of -Adrenergic, 5-HT1A, and 5-HT1B Receptors Alain Gobert, Ph.D. and Mark J. Millan, Ph.D. (-)-Pindolol, which possesses significant affinity for 5-HT1A, involved. (-)-Pindolol potentiated the increase in FCX levels b 5-HT1B, and 1/2-adrenergic receptors (AR)s, dose- of 5-HT elicited by the 5-HT reuptake inhibitors, fluoxetine dependently increased extracellular levels of dopamine and duloxetine, and also enhanced their ability to elevate (DA) and noradrenaline (NAD) versus 5-HT, in dialysates FCX levels of DA—though not of NAD. In contrast to of the frontal cortex (FCX), but not accumbens and (-)-pindolol, betaxolol and ICI118,551 did not affect the striatum, of freely-moving rats. In distinction, the actions of fluoxetine, whereas both WAY100,635 and b preferential 1-AR antagonist, betaxolol, and the SB224,289 potentiated the increase in levels of 5-HT—but b preferential 2-AR antagonist, ICI118,551, did not increase not DA or NAD levels—elicited by fluoxetine. In basal levels of DA, NAD, or 5-HT. Further, they both dose- conclusion, (-)-pindolol modulates, both alone and together dependently and markedly blunted the influence of with 5-HT reuptake inhibitors, dopaminergic, adrenergic, (-)-pindolol upon DA and NAD levels. The selective 5-HT1A and serotonergic transmission in the FCX via a complex b receptor antagonist, WAY100,635, slightly attenuated the pattern of actions at 1/2-ARs, 5-HT1A, and 5-HT1B (-)-pindolol-induced increase in DA and NAD levels, while receptors.
    [Show full text]
  • Methylphenidate-Based
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Zahi Sulaiman 1st Floor (NE), Peel Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 1121 [email protected] Minister of State for Crime Prevention Home Office 2 Marsham Street London SW1P 4DF 31 March 2015 Dear Minister, I am writing to recommend that you lay a temporary class drug order (TCDO) pursuant to section 2A of the Misuse of Drugs Act 1971 on a number of methylphenidate-based NPS: ethylphenidate, 3,4-dichloromethylphenidate (‘3,4- DCMP’), methylnaphthidate (‘HDMP-28’), isopropylphenidate (‘IPP’ or ‘IPPD’) and propylphenidate. Methylphenidate-based NPS Methylphenidate is a licensed stimulant pharmaceutical and is controlled in the UK as a Class B controlled drug. The methylphenidate-related materials being marketed as NPS have psychoactive effects so similar to the parent compound that they can be expected to present similar risks to users. Although ethylphenidate is by far the most widely available of this group, other variants are already in the market place. In the short term, to address the widespread availability of methylphenidate-based NPS and the associated problems which are being reported, the ACMD has considered the evidence on methylphenidate-based NPS and recommends control of these NPS by means of a TCDO. The attached report contains the ACMD’s consideration of the evidence concerning methylphenidate-based NPS. 1 In providing this advice, I would like to convey my thanks to Police Scotland, the National Programme on
    [Show full text]
  • CONGRESS REPORT Vienna, Austria 30Th June - 2Nd July 18Th International ESCAP Congress
    The 18th International ESCAP Congress CONGRESS REPORT Vienna, Austria 30th June - 2nd July 18th International ESCAP Congress The 18th International European Society for Child and Adolescent Psychiatry (ESCAP) Congress lived up to its goal of creating collaboration and knowledge exchange on very specific topics in child and adolescent psychiatry, under the theme title “Developmental psychiatry in a Globalized World”. Over 1600 child and adolescent psychiatrists and allied professionals from 71 countries descended on a very hot Vienna during the three full-day event on the 30th June to 2nd July. They were treated to an array of 7 keynote and 18 state of the art talks as well as 80 symposiums and two special lectures, and over 400 posters presenting the most cutting-edge research in the field. The congress was organised in collaboration with the Austrian Society of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (ÖGKJP) who choose one of the most iconic venues in the city, the Hofburg. The royal palace where the empress Elisabeth of Austria Sisi spent her court life at the end of the nineteenth century. Congress president and ESCAP Board member Andreas Karwautz developed a well-balanced scientific and social event. In the opening ceremony, he highlighted four special topics related to the history of Vienna that he incorporated into the program; Nazi history and child psychiatry, substance abuse, the role of psychotherapy, and suicide in the context of transport. The opening ceremony continued with a decadent theme with the Austrian Boys and Girls choir blessing participants with their voices and a talented Harpist and singer Sophie-Theres Völkl played on our own heartstrings.
    [Show full text]
  • The Context of HIV Risk Among Drug Users and Their Sexual Partners
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES The Context of HIV Risk Among Drug Users and Their Sexual Partners 143 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health The Context of HIV Risk Among Drug Users and Their Sexual Partners Editors: Robert J. Battjes, D.S.W. Zili Sloboda, Sc.D. William C. Grace, Ph.D. NIDA Research Monograph 143 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGMENT This monograph is based on the papers from a technical review on “The Context of HIV Risk Among Drug Users and Their Sexual Partners” held on April 22-23, 1993. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • (±)-Pindolol Acts As a Partial Agonist at Atypical >-Adrenoceptors in The
    Jpn. J. Pharmacol. 85, 35 – 40 (2001) (±)-Pindolol Acts as a Partial Agonist at Atypical >-Adrenoceptors in the Guinea Pig Duodenum Takahiro Horinouchi and Katsuo Koike* Department of Chemical Pharmacology, Toho University School of Pharmaceutical Sciences, 2-2-1, Miyama, Funabashi, Chiba 274-8510, Japan Received July 19, 2000 Accepted September 29, 2000 ABSTRACT—The agonistic and antagonistic effects of (±)-pindolol (1-(1H-indol-4-yloxy)-3-[(1-methyleth- yl)amino]-2-propanol) were estimated to clarify whether (±)-pindolol acts as a partial agonist on atypical b-adrenoceptors in the guinea pig duodenum. (±)-Pindolol induced concentration-dependent relaxation with a pD2 value of 5.10 ± 0.03 and an intrinsic activity of 0.83 ± 0.03. However, the relaxations to (±)-pindolol were not antagonized by the non-selective b 1- and b 2-adrenoceptor antagonist (±)-propranolol (1 mM). In the presence of (±)-propranolol (1 mM), the non-selective b1-, b2- and b3-adrenoceptor antagonist (±)-bupranolol (30 mM) induced a rightward shift of the concentration-response curves for (±)-pindolol (apparent pA2 = 5.41 ± 0.06). In the presence of (±)-propranolol, (±)-pindolol (10 mM) weakly but significant- ly antagonized the relaxant effects to catecholamines ((-)-isoprenaline, (-)-noradrenaline and (-)-adrenaline), a selective b 3-adrenoceptor agonist BRL37344 ((R*,R*)-(±)-4-[2-[(2-(3-chlorophenyl)-2-hydroxyethyl) amino]propyl]phenoxyacetic acid sodium salt) and a non-conventional partial b 3-adrenoceptor agonist (±)-CGP12177A ([4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one] hydrochloride). These results demonstrate that (±)-pindolol possesses both agonistic and antagonistic effects on atypical b-adrenoceptors in the guinea pig duodenum.
    [Show full text]